Loading stock data…
CELC
$125.65+4.30 (+3.54%)
Market ClosedLast close May 1
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Celcuity Inc. in the Healthcare sector is trading at $125.65. The stock is currently near its 52-week high of $129.09, remaining 48.1% above its 200-day moving average. Technical signals show neutral RSI of 55 and bearish MACD signal, explaining why CELC maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 55) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$125.65
Potential Upside
5%
Whystock Fair Value$131.93
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$135.10+7.5%
Range$94.00 – $165.00
Fundamentals
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.92B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.42
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-176.06%
Volume
Today's trading volume
2.08M
Recent News
Why Celcuity Stock Popped on Monday
An analyst initiated coverage of the biotech.
Celcuity Inc. (CELC): Likely Leader in Next Generation of Breast Cancer Treatments
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Celcuity Inc. (NASDAQ:CELC) ranks 3rd on this list. Celcuity Inc. (NASDAQ:CELC) stock went on a wild surge last year and hedge funds are continuing to buy the shares as they view the firm as a likely leader in the next […]
Is Celcuity (CELC) Still Attractive After Its Strong One Year Share Price Rally
If you are wondering whether Celcuity's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers suggest about value. The stock last closed at US$112.63, with a 6.2% return over 7 days, a 2.1% decline over 30 days, and year to date and 1 year returns that are both very large, including around a 12.0% gain this year. These moves sit against a backdrop where Celcuity has been attracting attention for its position in the biotech space and...
Why Celcuity Stock Popped Today
The cancer-focused biotech published its final set of figures for 2025.
Celcuity Inc. Q4 2025 Earnings Call Summary
Moby summary of Celcuity Inc.'s Q4 2025 earnings call